02b: CT Diseases Flashcards

1
Q

Most common subtype of cutaneous lupus erythematosus:

A

Discoid (70-80%)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Pt with discoid lupus notices hair loss that isn’t growing back with time, despite resolution of inflammed scalp lesions. What is the cause of this and what can be done to treat?

A

Follicular plugging and scarring alopecia; hair can’t be grown back

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

T/F: 60% or more of patients with discoid lupus will develop SLE over time.

A

False - only 10-20% (and with milder systemic disease)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Discoid lupus: histology characterized by which process?

A

Interface dermatitis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Distinctly photosensitive subset of cutaneous lupus:

A

Subacute cutaneous lupus eryth (SCLE)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

T/F: Subacute lupus (SCLE) and Acute cutaneous lupus (ACLE) lesions heal without scarring.

A

True

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

T/F: Subacute lupus (SCLE) lesions most commonly appear on face and extremities.

A

False - face relatively spared

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Presence of anti-(X) Ab is seen in 85% of SCLE patients.

A

X = Ro

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Bilateral malar erythema, especially following (X), is classic for which subset of cutaneous lupus?

A

X = sun exposure (butterfly rash)

Acute cutaneous lupus (ACLE)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

T/F: Acute cutaneous lupus (ACLE) is the subtype that’s least associated with systemic disease.

A

False - nearly always associated with systemic disease

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Rx for Cutaneous Lupus:

A
  1. Sun protection and behavioral modification (vit D status, smoking cessation)
  2. Topical agents (corticosteroids, calcineurin inhibitors)
  3. Systemics (anti-malarials or immunosuppressives)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Pathognomonic features for dematomyositis:

A
  1. Heliotrope rash (around eyelids)

2. Gottron’s papules (flat-topped papules over knuckles, mainly of hands)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Violaceous confluent erythema over knees, cuticular dystrophy, and non-scarring alopecia. These are all features of:

A

Dermatomyositis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Dermatomyositis typically involves (proximal/distal) (symmetric/asymmetric) muscle weakness.

A

Proximal; symmetric

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Aside from muscle and skin, which organ system(s) are affected by dermatomyositis?

A
  1. Joints (arthralgia/arthritis)
  2. Esophagus (dysphagia, dysphonia)
  3. Lungs (interstitial lung disease, muscle weakness)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Dermatomyositis has particularly strong association with which malignancies?

A
  1. Ovarian
  2. Lung
  3. GI (pancreatic, stomach, colon)
  4. NHL
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Dermatomyositis Rx:

A
  1. Sun protection and behavior change
  2. Skin hydration and anti-pruritics
  3. Topical agents (corticosteroids, calcineurin inhibitors)
  4. Systemic (anti-malarials or immunosuppressive)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

T/F: First manifestations of scleroderma are related to fibrosis and atrophy.

A

False - edema first (ex: can’t close swollen hands), then fibrosis, then atrophy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

The “salt and pepper sign” refers to (X) skin finding and is suggestive of which disease?

A

X = de-pigmentation except for around hair follicles (esp prominent in dark skin)

Scleroderma

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

Mat telangiectases are (X)-shaped and can appear on (Y) parts of body. They’re characteristic for which disease?

A
X = square-ish
Y = any (palms, oral mucosa, face)

Scleroderma

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

Cuticular dystrophy and digital ulcers/pits are characteristic of:

A

Scleroderma

22
Q

Calcinosis cutis is a relatively common finding in which disease?

A

Scleroderma (Ca deposits in skin)

23
Q

Leading cause of death in scleroderma patients:

A

Lung disease

24
Q

Melanocytes are derived from which embryological tissue?

A

Neuroectoderm

25
Q

Freckles: increased (pigmentation/proliferation) of melanocytes.

A

Pigmentation

26
Q

The common, irregular hyper-pigmented macules seen on dorsal surface of elderly woman’s hands are likely:

A

Solar lentigo (incidence increases with age and indication of chronic UV exposure)

27
Q

Histology of solar lentigo would show:

A

Long rete of epidermis, extending into dermis with increased pigmentation of melanocytes

28
Q

Acquired nevi can be divided into which subtypes?

A
  1. Junctional (flat)
  2. Compound (dome-shaped)
  3. Intradermal (pedunculated)
29
Q

Compound nevi histology: melanocyte proliferation in which layer(s)?

A
  1. Junction (epidermis and dermis)

2. Extends into dermis

30
Q

Intradermal nevi histology: melanocyte proliferation in which layer(s)?

A

Dermis only (not at junction)

31
Q

T/F: Congenital melanocytic nevi have no malignancy potential, but acquired nevi do.

A

False - vice versa

32
Q

(X) skin finding is blue/black, large flat patches commonly seen in Asian infants. It can be mistaken for (Y).

A
X = mongolian spot
Y = bruising (child abuse)
33
Q

Mongolian spot: what gives the skin finding the characteristic (X) color?

A

X = blue-ish

Tyndall effect (melanocytes very deep down and reflection of light gives them blue color)

34
Q

Familial Atypical Mole Melanoma Syndrome: (X) mutation in about 40% and inherited in which fashion?

A

X = CDKN2A

AD

35
Q

ABCDE criteria: cut-off for diameter

A

6 mm

36
Q

Most common melanoma subtype:

A

Superficial spreading melanoma (70%)

37
Q

20% of melanoma cases are (X) subtype, which primarily grows (radially/vertically).

A

X = nodular

Vertically (no appreciable radial growth phase; aggressive)

38
Q

(X)% of melanomas are in (Y) subtype, due to chronic (as opposed to episodic) UV exposure.

A
X = 5
Y = lentigo maligna melanoma
39
Q

T/F: Lentigo maligna melanoma more common in head/neck and have long radial growth phase.

A

True

40
Q

(X)% of melanomas are in (Y) subtype and non-UV induced.

A
X = 5
Y = acral lentiginous melanoma
41
Q

Melanoma on nail-bed is likely to be which subtype?

A

Acral lentiginous melanoma

42
Q

(X) melanoma associated with Kit mutation.

A

X = Acral lentiginous melanoma

43
Q

Skin biopsy of melanoma: which two characteristics have prognostic value in staging melanoma?

A
  1. Breslow depth

2. Ulceration

44
Q

Sentinel Lymph Node biopsy should be considered for melanomas that have which features?

A
  1. Greater than 0.8 mm deep

2. Ulcerated

45
Q

List the FDA approved drugs for melanoma that target the key (X) pathway.

A

X = MAPK

  1. BRAF inhibitors (vemurafenib, dabrafenib)
  2. MEK inhibitor (Trametinib)
46
Q

FDA approved “immuno” Rx drugs for melanoma:

A
  1. Anti-CTLA4 (ipilimumab)

2. anti-PD1 (nivolumab, pembrolizumab)

47
Q

T/F: Most effective treatment choice for melanoma is BRAF inhibitors.

A

False - ONLY given to patients with BRAF mutation (otherwise, melanoma will progress); and combo Rx (BRAFi and MEKi) is preferred

48
Q

What’s the biggest issue with BRAFi therapy?

A

Cutaneous squamous cell carcinoma (due to paradoxical activation of MAPK path in normal cells)

49
Q

Frequency of Cutaneous squamous cell carcinoma that results from BRAFi use can be reduced by:

A

Adding MEKi

50
Q

Targeted v immunotherapy for melanoma: which therapy results in higher survival after 3y?

A

Immunotherapy (but less people respond to it)